BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee

Reuters12-05

BRIEF-<a href="https://laohu8.com/S/OSTX">OS Therapies</a> U.S. FDA Granted A Waiver Of Application Fee

Dec 5 (Reuters) - OS Therapies Inc OSTX.A:

OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2
OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2
OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2

Source text: [ID:]

Further company coverage: OSTX.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589979098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589979098","market":"fut","top_or_hot":-1,"title":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> U.S. FDA Granted A Waiver Of Application Fee </title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>OS Therapies Inc <span>OSTX.A</span>:</p><ul><li><p>OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2</p></li><li><p>OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2</p></li><li><p>OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD &amp; DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>OSTX.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> U.S. FDA Granted A Waiver Of Application Fee </title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>OS Therapies Inc <span>OSTX.A</span>:</p><ul><li><p>OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2</p></li><li><p>OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2</p></li><li><p>OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD &amp; DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>OSTX.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","article_id":"2589979098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589979098","pubTimestamp":1764939961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee Dec 5  - OS Therapies Inc OSTX.A:OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2Source text: [ID:]Further company coverage: OSTX.A ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSTX":"OS Therapies"},"translate_title":"BRIEF-OS Therapies美国FDA批准免除申请费","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9},"content_text":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee Dec 5 (Reuters) - OS Therapies Inc OSTX.A:OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2Source text: [ID:]Further company coverage: OSTX.A ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589979098","isCrawlerRequest":true}